
usd apr pm et
summari compani one largest pharmaci world retail
store mainli mexico
price-to-earnings oper ep
risk assess reflect compani strong
market share posit rel stabl retail
drug industri partli off-set growth non-tradit
competitor potenti advers legisl
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr pm stock trade
forecast sale growth fy
major growth come
acquisit store
march expect compar
pharmaci sale increas larg due
compar retail sale declin due
weaker cough/flu season
de-emphasi tobacco product lastli
expect segment declin
modestli due difficult market condit
expect gross margin pressur
fy due heavi reimburs
pressur compar fy estim
gross margin fy
report fy also expect ebit
margin slightli improv manag
improv cost structur
corpor workforc reduct
forecast fy ep remain flat
grow slightli fy fy
secular headwind expect fulli
off-set ep growth expect
accrual compar fy expect
limit ep growth
although expect much previous
note headwind persist fy
maintain hold rate think share
limit downsid risk given stock
trade histor low valuat level
environ weak market condit
play larg factor limit ep
growth expect pressur
continu second half fy believ
sever impact decreas
believ new leadership structur coupl
strateg emphasi partnership
cost reduct help allevi
headwind second half fy
risk recommend target price
headwind relat reimburs rate
could sever impact margin
off-set strong same-stor prescript
target price
fy aug ep estim steep
late-cycl discount forward
mean price-to-earnings justifi heavi
retail segment weak market
fiscal year end aug ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut chairman
corpor overview inc one market leader retail
pharmaci sale billion fy along compani equiti
method invest presenc countri employ peopl
total fy sale europ exclud
rest world
wba portfolio brand includ walgreen duan read boot allianc healthcar well
increasingli global health beauti product brand soap glori liz earl sleek make-up
botan
wba oper organ three divis also report segment
retail pharmaci usa fy total sale consist retail store fy
retail pharmaci brand walgreen duan read market leader approxim
popul within five-mil radiu walgreen duan read acquir rite
aid retail pharmaci compon segment pharmaci sale prescript drug
retail sale health care retail product includ non-prescript drug beauti
toiletri gener merchandis fy pharmaci compon sale
retail compon sale fill million prescript billion adjust
equival fy sale reimburs receiv manag care organ
government agenc pbm compani privat insur fy pharmaci
retail pharmaci intern fy total sale consist pharmacy-l health beauti
retail busi eight countri oper retail store divis fy
princip retail pharmaci brand boot thailand norway republ ireland
netherland benavid mexico ahumada chile fy pharmaci portion divis
compris total sale retail portion compris total sale
divis focus retail sale compar divis focus
pharmaci sale
pharmaceut wholesal fy total sale oper allianc healthcar brand
suppli medicin health care product relat servic pharmaci
doctor health center hospit year distribut center countri primarili
europ fy
corpor strategi unlik competitor health corpor
activ seek becom increasingli vertic integr health care compani instead
place greater emphasi strateg partnership joint ventur evidenc partnership
labcorp among other also
evidenc number equiti method invest made largest equiti
method invest approxim total carri valu equiti method invest
ownership equiti method invest includ pharmaceut compani china option
lead home infus servic provid
impact major develop march compet acquisit
store billion initi agreement took place june agre sell
drugstor billion cash howev due concern feder trade
commiss fewer store sold
march pharmaci benefit manag prime llc close transact form
combin specialti pharmaci mail servic compani alliancerx walgreen prime alliancerx
consolid report within retail pharmaci usa divis
exercis warrant purchas share amerisourcebergen corpor
common stock aggreg exercis price payment billion hold
warrant purchas share purchas share open market
end fy own approxim outstand share thu
requir use equiti method account
financi trend fy total sale increas constant-curr adjust oper
incom increas constant-curr adjust ep increas fy
return billion sharehold repurchas dividend
june board approv new stock repurchas program author repurchas
billion common stock repurchas program expir date fy expect
repurchas billion worth share
wba balanc sheet solid fy net debt-to-ebitda ratio share
yield
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neg fundament outlook
drug retail sub-industri next month
long term posit outlook
part due age overal popul
increas life expect increas
avail gener drug continu
develop innov drug increas
number individu health
insur howev next month
see certain factor imped growth
non-tradit player declin
front-end retail sale due chang
retail pharmaci industri reli heavili
privat government third-parti payer
reimburs prescript drug sold
pharmaci consum
payer take action restrict elig
reduc price reimburs rate sale
margin retail pharmaci industri
neg impact weve seen
phenomenon play recent year especi
sinc heavi consolid
healthcar industri given
bargain power player higher
valu chain pharmaci benefit manag
pbm insur
reimburs pressur noth new
sub-industri howev new view
see less opportun
mitig headwind exampl retail
pharmaci benefit recent year
lower price paid gener drug sale
drug typic carri higher margin
pharmaci prefer sell drug
brand one furthermor cost
pharmaci acquir gener drug
decreas due increas gener drug
avail marketplac therebi boost
margin even howev recent
weve seen decreas gener drug
deflat higher price paid drug
retail acquir gener drug therefor
combin increas reimburs
pressur lower gener drug price
deflat lead margin contract
next month view
late front-end store sale drug
retail also pressur
anoth miss opportun counter
pressur relat reimburs rate
see retail sale continu pressur
consum purchas prescript
drug on-line channel therebi
result less foot traffic insid drug store
 economi current
late-stag econom cycl
econom downturn could neg
predict acceler consolid
converg healthcar industri
would allevi reimburs
pressur third-parti payer also
make sens competit landscap
perspect industri becom
fragment small competitor
competitor non-tradit busi
drive scale effici
time battl growth key
determin whether drug retail
abl sustain industry-rel
 drug retail sub-industri
year-to-d march
compar broader consum stapl
sector
base index
five-year market price perform apr
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra reiter hold opinion share walgreen boot
allianc inc lower target price base
fy ep aug estim steep late-cycl discount
forward mean justifi heavi reimburs pressur
weak market condit lower fy ep estim
fy post feb-q ep vs
consensu comp sale retail pharmaci usa
segment grew fell segment lower
fy ep guidanc growth flat growth acknowledg
difficult quarter sinc headwind note quarter
entir new opportun mitig headwind
believ led weak result less sever cough/flu season go
forward expect pressur subsid acceler action plan
newli announc leadership structur given current valuat see
et cfra keep hold opinion share walgreen boot
allianc inc increas target base
ev/ebitda fy aug ebitda estim line
three-year averag forward ev/ebitda maintain ep estim
fy fy accord wall street journal
health insur inc earli discuss take equiti
stake think drugstor insur
seek diversif increas scale given rapidli evolv healthcar
industri threat new entrant includ inc
exist partnership two walgreen locat
focus serv senior two compani discuss
possibl expand locat given regulatori hurdl
recent year space think partnership propos
deal provid similar benefit less risk lower cost /matthew
allianc inc increas target price
impli ev/ebitda fy aug ebitda estim
discount three-year averag forward ev/ebitda justifi
uncertain drug price environ risk intensifi competit
pressur increas fy ep estim start
fy ep forecast fy forecast sale growth ep
growth first half fy anticip nearli basi
point headwind yoy gross margin improv back half
fy easier comparison although like new emphasi
strateg partnership vs acquisit continu see macro
headwind could limit earn growth intensifi competit
pm et cfra maintain hold opinion share walgreen boot
allianc inc lower target price
fy aug ep estim discount averag
reflect oper challeng lower fy ep
keep fy share tumbl last
coupl day base comment made cfo jame keho specif relat
headwind reimburs rate gener drug price deflat mr keho
howev reaffirm fy ep growth guidanc although
buyback support five point believ way
meet guidanc strong prescript volum growth
challeng retail intern segment persist fy
share also yesterday fda letter sent regard
underag tobacco sale think could lead action
reduc tobacco product may decreas store traffic hurt
et cfra reiter hold opinion share microsoft corpor
announc partnership
develop new health care deliveri model technolog
retail innov perhap notabl becom strateg
cloud provid plan migrat infrastructur
azur also deploy
employe store follow similar announc
earlier month juli note
retail partner also competitor cloud leader amazon
azur cloud platform health care invest new retail
solut align custom reach numer locat outpati
servic industri expertis commit multipl year
 invest build health care solut improv outcom lower
cost care also pilot store-in-stor digit
health corner help sell health care-rel hardware/devic /scott
et cfra maintain hold opinion share walgreen boot
allianc inc decreas target price
valu share ev/ebitda aug ebitda
estim discount three-year averag forward ev/ebitda
premium peer averag forward ev/ebitda think
valuat fairli account market leadership off-set
headwind higher cost weak market condit key market
trim ep estim
post nov-q adjust ep vs
consensu sale increas yoy billion miss consensu
announc new restructur program target billion
annual cost save three year announc retail pharmaci usa
compar sale rose yoy compar retail sale fell yoy
compar pharmaci sale declin yoy compar retail sale fell
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
